Karyopharm Therapeutics, Inc. (KPTI)
7.00
+0.52
(+8.02%)
USD |
NASDAQ |
Dec 11, 16:00
7.01
+0.01
(+0.14%)
After-Hours: 20:00
Karyopharm Therapeutics Research and Development Expense (Quarterly): 30.42M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 40.88M |
| Actinium Pharmaceuticals, Inc. | 4.042M |
| Axsome Therapeutics, Inc. | 40.04M |
| Krystal Biotech, Inc. | 13.18M |
| Akebia Therapeutics, Inc. | 14.63M |